2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06C.06 Outcome and Clinical Profile of Common and Uncommon EGFR Mutations in NSCLC: Retrospective Analysis from an Argentinean Cancer Center

EP.06C.06 Outcome and Clinical Profile of Common and Uncommon EGFR Mutations in NSCLC: Retrospective Analysis from an Argentinean Cancer Center

Back to course

Pdf Summary

The study titled "Outcome and clinical profile of Common and Uncommon EGFR mutations in advanced NSCLC," conducted by a team at Instituto de Oncología Angel H. Roffo, University of Buenos Aires, is a retrospective analysis of patients with EGFR mutations in non-small cell lung cancer (NSCLC). The research spanned from January 2015 to January 2023 and aimed to assess clinical characteristics and prognostic factors associated with survival outcomes in patients with common and uncommon EGFR mutations.<br /><br />EGFR mutations are vital predictive markers for response to targeted inhibitor therapies in NSCLC. This study found that patients with uncommon mutations had a significantly higher prevalence of ever-smokers (88% vs. 24%) and were predominantly male (72% vs. 33%) compared to those with common mutations. Additionally, patients with uncommon mutations more frequently exhibited synchronous central nervous system (CNS) metastases (33% vs. 4.5%).<br /><br />Uncommon EGFR mutations accounted for 19% of cases, with exon 18 G719X being the most prevalent among them. The survival analysis revealed that patients with uncommon mutations had worse prognoses, with a median progression-free survival (PFS) of 6.2 months and overall survival (OS) of 11.3 months, compared to 11 months of PFS and 28.4 months of OS in patients with common mutations.<br /><br />Multivariate analysis indicated male sex and uncommon EGFR mutations were associated with poorer prognosis. The study emphasizes the need for personalized treatment strategies for patients with uncommon EGFR mutations due to their distinct clinical profiles and lower survival rates, highlighting a critical area for ongoing research and tailored therapeutic approaches.

Asset Subtitle

Mónica Castro

Meta Tag

Speaker Mónica Castro

Topic Pathology and Biomarkers

Keywords

EGFR mutations

NSCLC

uncommon mutations

common mutations

survival outcomes

prognostic factors

targeted therapies

CNS metastases

personalized treatment

progression-free survival